Therapeutic effect of the combination of vericiguat and Qili Qiangxin Capsules in treating chronic heart failure and its impacts on serum NT-proBNP
He Jiangbo
Liu Lihui
Yang Zhannan
Abstract：Objective To investigate the therapeutic effect of the combination of vericiguat and Qili Qiangxin Cap-sules in treating chronic heart failure(CHF)and its impacts on serum N-terminal pro-B-type natriuretic peptide(NT-proBNP).Methods From January 2023 to November 2024,106 CHF patients treated in our hospital were randomly divided into two groups:the vericiguat group(n=53,received vericiguat in addition to conventional therapy)and the combination group(n=53,received vericiguat plus Qili Qiangxin Capsules).The two groups were compared in terms of therapeutic efficacy,Yang defi-ciency edema syndrome score,Minnesota Living with Heart Failure Questionnaire(MLHFQ)score,cardiac function indicators[left ventricular ejection fraction(LVEF)and stroke volume(SV)],serum NT-proBNP level,vascular endothelial indicators[endothelin-1(ET-1)and nitric oxide(NO)],and adverse drug reactions.Results The total effective rate in the combination group was 94.00％,which was higher than that in the vericiguat group(78.43％)(x2/P=5.125/0.024).After treatment,both groups showed decreased scores of Yang deficiency edema syndrome,MLHFQ score,and serum levels of NT-proBNP and ET-1,with the combination group exhibiting lower values than the vericiguat group(t/P=6.167/＜0.001,8.048/＜0.001,3.692/＜0.001,4.278/＜0.001).After treatment,both groups showed increased LVEF,SV,and NO levels,with the combination group exhibiting higher values than the vericiguat group(t/P=3.224/0.002,3.382/0.001,2.877/0.005).There was no significant difference in the incidence of adverse reactions between the combination group and the vericiguat group(14.00％vs.7.84％)(P＞0.05).Conclusion The combination of vericiguat and Qili Qiangxin Capsules demonstrates better therapeutic efficacy in CHF patients.It can effectively reduce serum NT-proBNP levels,significantly improve vascular endothelial function and relat-ed symptoms,enhance cardiac function and quality of life,and is safe.
Keywords：Chronic heart failureVericiguatQili Qiangxin CapsulesN-terminal pro-B-type natriuretic peptideCar-diac function indicatorsVascular endothelial indicators
Publication Date：2025-09-18
Online Publishing Date：2025-10-11(First online date of this platform, not the publication date of the document)
Pages：5( 1040-1044 )